Notice of AGM and Management Change

Jun 6, 2018

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 4176Q
Advanced Medical Solutions Grp PLC
06 June 2018
 


6 June 2018

 

Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

Notice of AGM and Management Change

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, will hold its Annual General Meeting at 11.00 am today at 85 Gresham Street, London, EC2V 7NQ. At the AGM, Chris Meredith, AMS’s Chief Executive Officer, will give a short presentation. No new material information will be provided.

 

AMS also announces today that Mary Tavener intends to retire from the role of Chief Financial Officer and Board Director on 31 December 2018, after 19 years with the Company. At the same time, Eddie Johnson, who has been with AMS for more than six years, and is currently Group Financial Controller, will assume the role of Chief Financial Officer and join the Board. 

 

Commenting on the announcement, Peter Allen, Non-Executive Chairman of AMS, said: “I would like to thank Mary for her 19 years of dedicated and outstanding service to AMS. In her time with the Group, she has been integral to our listing on AIM, several acquisitions and this has culminated in AMS growing for 13 consecutive years. At the same time, I would also like to congratulate Eddie on his forthcoming appointment as Chief Financial Officer and we look forward to welcoming him to the Board in due course.”

 

Edward (“Eddie”) Johnson, 46, is not currently, nor has he been in the last five years, a director or partner in any company or partnership respectively. Other than as set out in this announcement, there are no further disclosures required under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

– Ends –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

 

Chris Meredith, Chief Executive Officer

Mary Tavener, Chief Financial Officer


 



 

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

 

Mary-Jane Elliott / Matthew Neal / Nicholas Brown

AMS@consilium-comms.com

 



 

Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

 

Daniel Adams / Patrick Robb / Gary Clarence


 

 

 

 

 

About Advanced Medical Solutions Group plc – see www.admedsol.com

 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

 

AMS‘s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 600 employees.  For more information, please see www.admedsol.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 

END

 
 

MSCKELFBVQFEBBK

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.